Abstract
Background
Levodopa is the cornerstone treatment for Parkinson’s disease, but the short half-life of levodopa limits its usefulness in late stages of the disease. Duodenal levodopa infusion (DLI) allows more stable plasma levels and better motor symptom control.
Objective
To explore the costs and health benefits of replacing conventional oral polypharmacy with DLI in patients with advanced Parkinson’s disease, from a Swedish healthcare payer perspective.
Methods
Based on a clinical, randomized, crossover study with 24 patients (DIREQT), a decision analytic model predicted 2-year drug costs and QALYs for conventional oral therapy and for DLI. Health-related quality of life (HR-QOL) was recorded using a 15-dimensional (15D) utility instrument at baseline and during the two 3-week trial periods, and then at eight follow-up visits during the subsequent 6 months. Use of medication was based on data from DIREQT and previous studies. Unit costs were based on market prices (drugs) and customary charges in Sweden. All costs were expressed in Swedish kronor (SEK), year 2004 values (€1.00 ≈ SEK9.17, $US1.00 = SEK7.47). Future costs and outcomes were discounted at 3%. One-way and probabilistic sensitivity analyses were conducted.
Results
The mean utility scores were 0.77 for DLI and 0.72 for conventional therapy (p = 0.02). A considerable variation in the scores was observed during the study. The expected per-patient 2-year cost of DLI was SEK562000 while it was SEK172 000 for conventional therapy. The mean number of QALYs was 1.48 and 1.42, respectively, representing an incremental cost of SEK6.1 million per QALY for DLI (all values discounted at 3%). Using other assumptions in sensitivity analyses, the cost per QALY could be as low as SEK456000.
Conclusion
This analysis can be considered exploratory only; it is based on very limited data. Nevertheless, our findings suggest that DLI results in a significant improvement in HR-QOL. However, the cost per QALY is likely to be higher than customary cost-effectiveness thresholds. Whether these benefits justify the additional costs depends on how the health benefits are measured and how these benefits are valued by society.
Similar content being viewed by others
References
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 368–76
Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson’s disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008; 60(2): 57–66
Jankovic J, Stacy M. Medical management of levodopaassociated motor complications in patients with Parkinson’s disease. CNS Drugs 2007; 21(8): 677–92
Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989 Jun; Suppl.: 29–37
Rinne UK. Problems associated with long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1983; 95: 19–26
Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol 1986; 19(4): 365–72
Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93(1): 14–20
Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease: a multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37(1): 23–7
Bredberg E, Tedroff J, Aquilonius SM, et al. Pharmacokinetics and effects of levodopa in advanced Parkinson’s disease. Eur J Clin Pharmacol 1990; 39(4): 385–9
Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson’s disease. Clin Pharmacokinet 1995; 29(4): 243–56
Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988; 38(3): 419–21
Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988; 24(1): 87–9
Sage JI, Trooskin S, Sonsalla PK, et al. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson’s disease. Neurology 1989; 39(11 Suppl. 2): 60–3
Mouradian MM, Heuser IJ, Baronti F, et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 1990; 27(1): 18–23
Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990; 40(6): 995–7
Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off fluctuations. Neurology 1993; 43(9): 1698–703
Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol 1993; 45(2): 117–22
Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26(3): 156–63
Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998; 97(3): 175–83
Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease: long-term experience. Acta Neurol Scand 2001; 104(6): 343–8
Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/ carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31(2): 63–73
Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64(2): 216–23
Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33(5): 328–36
Sintonen H. The 15D-measure of health related quality of life: II. Feasibility, reliability and validity of its valuation system. Melbourne (VIC): National Centre for Health Program Evaluation, 1995
Wittrup-Jensen KU. Measurement and valuation of health-related quality of life [dissertation]. Odense: University of Southern Denmark, 2004
Nord E. Cost-value analysis in health care. Cambridge: Cambridge University Press, 1999
Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9(3): 163–8
Haapaniemi TH, Sotaniemi KA, Sintonen H, et al. The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75(7): 976–83
Isacson D, Bingefors K, Kristiansen IS, et al. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008; 118(6): 379–86
Continuous delivery of levodopa/carbidopa in patients with advanced Parkinson’s disease compared to conventional medications [report]. Uppsala: Neopharma, 2004 Nov 7. (Data on file)
Nyholm D, Lewander T. A retrospective study of patients treated with Duodopa/Duodopa N from January 1, 1991 to June 30, 2002 [report]. Uppsala: Neopharma, 2003 Aug 8. (Data on file)
Jonsson L, Gurner L. Vad kostar vård och omsorg av aldre multisjuka? Rapport 2001: 7. Stockholm: lans Aldrecentrum, 2004
Askmark H, Antonov K, Aquilonius SM. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption: a nation-wide perspective in Sweden. Parkinsonism Relat Disord 2003; 9(5): 271–6
Nordling S, Grabowski M, Hagell P, et al. Societal costs of Parkinson’s disease (in Swedish) [report]. IHE Arbetsrapport 2001: 2. Lund: Institute for Health Economics, 2001
Persson U, Hjelmgren J. Health services need knowledge of how the public values health [in Swedish]. Lakartidningen 2003; 100(43): 3436–7
Noyes K, Dick AW, Holloway RG. Pramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectiveness. Pharmacoeconomics 2005; 23(12): 1257–70
Stavem K, Bjornaes H, Lossius MI. Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy. Epilepsy Res 2001; 44(2-3): 179–89
Stavem K. Reliability, validity and responsiveness of two multi-attribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8(1-2): 45–54
Kotomaki T, Honkalampi T, Sintonen H. How do the scores of generic HRQOL instruments reflect the direct TTO valuations of own health by general population [Abstract no. 207]? Value Health 2006; 9(6): A207
Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson’s disease. Neurology 2002; 59(1): 103–8
Di Rocco A, Molinari SP, Kollmeier B, et al. Parkinson’s disease: progression and mortality in the L-DOPA era. Adv Neurol 1996; 69: 3–11
Troster AI, Fields JA, Wilkinson S, et al. Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. Stereotact Funct Neurosurg 2003; 80(1-4): 43–7
Woods SP, Fields JA, Lyons KE, et al. Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson’s disease: a one-year follow-up. Acta Neurochir (Wien) 2001; 143(12): 1273–7
Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord 2002; 17(2): 372–7
Just H, Ostergaard K. Health-related quality of life in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 2002; 17(3): 539–45
Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology 2001; 57(4): 663–71
Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson’s disease. Mov Disord 2007; 22(15): 2183–91
Ashkan K, Wallace B, Bell BA, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 1993–2003: where are we 10 years on? Br J Neurosurg 2004; 18(1): 19–34
Lyons KE, Wilkinson SB, Overman J, et al. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004; 63(4): 612–6
Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother 2006; 40(4): 651–7
Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson’s disease patients with wearing-off. Curr Med Res Opin 2005; 21(7): 1005–14
Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007; 27(3): 327–34
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20(3): 332–42
Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329(7459): 224–7
Ekman M, Zethraeus N, Dahlstrom U, et al. Cost-effectiveness of bisoprolol in chronic heart failure [in Swedish]. Lakartidningen 2002; 99(7): 646–50
World Health Organization. Bulletin of the World Health Organization (BLT) [online]. Available from URL: http://www.who.int/bulletin/archives/78(2)274.pdf [Accessed 2009 Sep 8]
McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331 (7523): 1016–9
Acknowledgements
This study was initiated and funded by Neopharma/Solvay. According to the contract between the researchers and the company, the former have the right to publish material from the study, but the company has the right to comment upon such material before it is published. All researchers had access to the full data file, and the analyses were undertaken by the researchers. D. Nyholm was employed by NeoPharma in 1999–2000, has an ongoing consultancy agreement with Solvay Pharma and has received honoraria from Neopharma/ Solvay for lectures and a book chapter. I. Kristiansen, D. Isacson and K. Bingefors received honoraria for this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kristiansen, I.S., Bingefors, K., Nyholm, D. et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden. Appl Health Econ Health Policy 7, 167–180 (2009). https://doi.org/10.1007/BF03256150
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256150